M8W Stock Overview A biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
MediWound Ltd. Competitors Price History & Performance
Summary of share price highs, lows and changes for MediWound Historical stock prices Current Share Price US$18.00 52 Week High US$20.40 52 Week Low US$10.80 Beta 0.81 1 Month Change 9.76% 3 Month Change 17.65% 1 Year Change 63.64% 3 Year Change 31.87% 5 Year Change -2.60% Change since IPO -70.54%
Recent News & Updates MediWound Ltd. Revises Revenue Guidance for 2024 Nov 26
MediWound Ltd. to Report Q3, 2024 Results on Nov 26, 2024 Nov 12
MediWound Ltd. Announces Phase II Head-To-Head Study Evaluating EscharEx®? vs. Collagenase in Patients with Venous Leg Ulcers Oct 10
Second quarter 2024 earnings released: US$0.68 loss per share (vs US$0.099 profit in 2Q 2023) Aug 15
MediWound Ltd. Announces Positive Results from the U.S. NexoBrid Expanded Access Protocol (NEXT) Aug 06
MediWound Ltd. to Report Q2, 2024 Results on Aug 14, 2024 Aug 02 See more updates MediWound Ltd. Revises Revenue Guidance for 2024 Nov 26
MediWound Ltd. to Report Q3, 2024 Results on Nov 26, 2024 Nov 12
MediWound Ltd. Announces Phase II Head-To-Head Study Evaluating EscharEx®? vs. Collagenase in Patients with Venous Leg Ulcers Oct 10
Second quarter 2024 earnings released: US$0.68 loss per share (vs US$0.099 profit in 2Q 2023) Aug 15
MediWound Ltd. Announces Positive Results from the U.S. NexoBrid Expanded Access Protocol (NEXT) Aug 06
MediWound Ltd. to Report Q2, 2024 Results on Aug 14, 2024 Aug 02
MediWound Ltd. Announces Publication of the EscharEx® Phase II ChronEx Study Results for Venous Leg Ulcers Jul 29 MediWound Ltd. announced that it expects to receive $24.999994 million in funding from Mölnlycke Health Care AB and other investors Jul 16
New minor risk - Profitability Jun 03
MediWound Ltd., Annual General Meeting, Jul 09, 2024 May 31
First quarter 2024 earnings released: US$1.05 loss per share (vs US$0.44 loss in 1Q 2023) May 30
MediWound Ltd. to Report Q1, 2024 Results on May 29, 2024 May 24
New major risk - Share price stability Apr 17
Full year 2023 earnings released: US$0.74 loss per share (vs US$3.93 loss in FY 2022) Mar 21
MediWound Ltd. to Report Q4, 2023 Results on Mar 21, 2024 Mar 15
Mediwound Ltd. Announces Positive Results in Head-To-Head Comparison of Escharex® Vs. Santyl® Within the Chronex Phase Ii Randomized Controlled Study Feb 13
Mediwound Announces That FDA Has Accepted for Review the Supplement to the Nexobrid BLA to Include Pediatric Patients with Severe Thermal Burns Jan 10
Mediwound Ltd. Announces Publication of Escharex Mechanism of Action Study Assessing Its Effects on Biofilm and Microbial Loads Dec 22
Third quarter 2023 earnings released: US$0.24 loss per share (vs US$0.88 loss in 3Q 2022) Nov 24
MediWound Ltd. Appoints Shmulik Hess as Chief Operating Officer and Chief Commercial Officer, Effective December 1, 2023 Nov 22
MediWound Ltd. to Report Q3, 2023 Results on Nov 21, 2023 Nov 15
MediWound Ltd Receives Positive CHMP Opinion Recommending Approval for NexoBrid® to Treat Pediatric Patients Nov 14
MediWound Ltd. Secures Additional U.S. Department of Defense Funding to Advance NexoBrid Development for the U.S. Army Sep 27
MediWound Ltd. Announces U.S. Commercial Availability of NexoBrid®? for the Treatment of Severe Thermal Burns in Adults Sep 22
High number of new and inexperienced directors Sep 01
New minor risk - Share price stability Aug 23
Second quarter 2023 earnings released: EPS: US$0.099 (vs US$0.92 loss in 2Q 2022) Aug 18
MediWound Ltd. to Report Q2, 2023 Results on Aug 15, 2023 Aug 08
MediWound Ltd. Announces Commercial Launch of NexoBrid®? in Japan Aug 03
Mediwound Ltd. Announces Positive Results in Its U.S. Phase I/Ii Study of Mw005 for the Treatment of Basal Cell Carcinoma Jul 11
MediWound Receives Positive Scientific Advice from European Medicine Agency (EMA) on EscharEx Phase III Study Design Jul 04
First quarter 2023 earnings released: US$0.44 loss per share (vs US$0.87 loss in 1Q 2022) May 31
MediWound Ltd. to Report Q1, 2023 Results on May 30, 2023 May 13
Full year 2022 earnings released: US$3.93 loss per share (vs US$3.48 loss in FY 2021) Mar 17
MediWound Ltd. Announces FDA Approval of NexoBrid® for the Treatment of Severe Thermal Burns in Adults Dec 30
MediWound Announces Positive Results in U.S. Phase I/II Study of Mw005 for the Treatment of Basal Cell Carcinoma Dec 20
MediWound Ltd Gains Marketing Approval of NexoBrid® in India Dec 14
High number of new directors Nov 16
MediWound Ltd. to Report Q3, 2022 Results on Nov 15, 2022 Nov 04
High number of new directors Nov 02
MediWound Ltd. Announces Formation of Strategic Advisory Board Oct 26
MediWound's EscharEx® Featured in Oral and Poster Presentations at the Symposium on Advanced Wound Care (SAWC) Fall 2022 Oct 20
MediWound Ltd. Announces European Medicines Agency Validates for Review the Type Ii Variation Sep 21
Second quarter 2022 earnings released: US$0.13 loss per share (vs US$0.12 loss in 2Q 2021) Aug 11 Mediwound Ltd. Announces Management Changes Aug 10
MediWound Announces U.S. FDA Acceptance of Biologics License Application for Nexobrid for the Treatment of Severe Thermal Burns Aug 04
MediWound Ltd. to Report Q2, 2022 Results on Aug 09, 2022 Aug 02 MediWound Announces Positive Initial Data from its U.S. Phase I/II Study of MW005 for the Treatment of Basal Cell Carcinoma
MediWound Ltd. Announces Positive Results from Its U.S. Phase 2 Pharmacology Study of EscharEx for Debridement of Lower Leg Ulcers Jul 08
MediWound Ltd. Announces Appointment of Tzvi Palash as Chief Operating Officer Jul 01
MediWound Ltd., Annual General Meeting, Jul 19, 2022 Jun 10 Mediwound Ltd. Appoints Sharon Malka to the Company's Board of Directors
First quarter 2022 earnings released: US$0.13 loss per share (vs US$0.10 loss in 1Q 2021) May 18
MediWound Ltd. Announces Positive Results from U.S. Phase 2 Clinical Study of Escharex® for the Debridement of Venous Leg Ulcers May 13
MediWound Ltd. to Report Q1, 2022 Results on May 17, 2022 May 12
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Mar 18
U.S. Department of Defense Awards Defense Research Grant to Mediwound Ltd. for the Development of Nexobrid for the U.S. Army Feb 18 MediWound Ltd. announced that it has received $9 million in funding from Biomedical Advanced Research And Development Authority Feb 12
Mediwound Announces Positive Topline Results from Its U.S. Phase 2 Trial of Escharex for Debridement of Chronic Wounds Jan 25
MediWound Announces Positive Initial Data from its U.S. Phase 2 Pharmacology Study of EscharEx Showing Effective and Rapid Debridement in Chronic and Hard to Heal Wounds Dec 21
MediWound Completes Enrollment of its EscharEx U.S. Phase 2 Adaptive Design Study Dec 07
Third quarter 2021 earnings released: US$0.12 loss per share (vs US$0.073 loss in 3Q 2020) Nov 18
Second quarter 2021 earnings released: US$0.12 loss per share (vs US$0.11 loss in 2Q 2020) Aug 11
MediWound Receives Complete Response Letter from U.S. FDA for NexoBrid Biologics License Application Jun 30
MediWound Completes Patient Enrollment for Interim Assessment of U.S. EscharEx Phase 2 Adaptive Design Study Jun 10
First quarter 2021 earnings released: US$0.10 loss per share (vs US$0.09 loss in 1Q 2020) May 06
Full year 2020 earnings released: US$0.34 loss per share (vs US$0.076 profit in FY 2019) Feb 26
Revenue beats expectations Feb 26
MediWound Ltd. Launches Clinical Development Program for Treatment of Non-Melanoma Skin Cancer Feb 23
MediWound Ltd. to Report Q4, 2020 Results on Feb 25, 2021 Feb 17
New 90-day high: €4.52 Feb 05
New 90-day high: €3.76 Jan 14
MediWound Ltd. Provides Progress Update on its EscharEx Clinical Development Program Jan 12
MediWound Ltd. Announces Successful Completion of In-Vivo Head-to-Head Comparator Study of EscharEx versus a Commercial Enzymatic Debridement Agent Dec 23
New 90-day high: €3.50 Dec 16
MediWound Continues Global Expansion with Distribution Agreement for NexoBrid in United Arab Emirates with Ghassan Aboud Group Dec 16
Third quarter 2020 earnings released: US$0.073 loss per share Nov 11
Revenue beats expectations Nov 11
MediWound Ltd. to Report Q3, 2020 Results on Nov 10, 2020 Nov 03
MediWound Ltd. Completes Enrollment Stage of its NexoBrid Phase 3 Pediatric Study Oct 29 Shareholder Returns M8W DE Pharmaceuticals DE Market 7D -4.8% -3.9% -0.02% 1Y 63.6% -12.4% 15.1%
See full shareholder returns
Return vs Market: M8W exceeded the German Market which returned 15.3% over the past year.
Price Volatility Is M8W's price volatile compared to industry and market? M8W volatility M8W Average Weekly Movement 8.4% Pharmaceuticals Industry Average Movement 5.2% Market Average Movement 4.8% 10% most volatile stocks in DE Market 11.3% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: M8W's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: M8W's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; and MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma.
Show more MediWound Ltd. Fundamentals Summary How do MediWound's earnings and revenue compare to its market cap? M8W fundamental statistics Market cap €203.71m Earnings (TTM ) -€27.17m Revenue (TTM ) €19.09m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) M8W income statement (TTM ) Revenue US$19.72m Cost of Revenue US$17.27m Gross Profit US$2.45m Other Expenses US$30.51m Earnings -US$28.06m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -2.60 Gross Margin 12.42% Net Profit Margin -142.29% Debt/Equity Ratio 0%
How did M8W perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/02/07 18:26 End of Day Share Price 2025/02/07 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github .
Analyst Sources MediWound Ltd. is covered by 14 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution David Maris BMO Capital Markets Equity Research Jason Wittes Brean Capital Michael Gorman BTIG
Show 11 more analysts 
